FRIDAY, Jan. 17, 2014 (HealthDay News) -- The U.S. Food and Drug
Administration approved on Friday a first-of-its-kind blood test
that can scan a child's genetic code and spot possible genetic
explanations for developmental delays or intellectual
The test can identify variations in chromosomes that are linked
to such disorders as Down syndrome, DiGeorge syndrome and other
developmental disabilities, the FDA said in a news release.
"This test is going to provide an additional diagnostic tool for treatment of children with identified developmental problems and disabilities," said Dr. Annemarie Stroustrup, an assistant professor of pediatrics and newborn medicine at Mount Sinai Hospital in New York City.
It could speed up the diagnosis of these problems, "which could
open the door for better and more targeted treatment," Stroustrup
said. "It will also give families a more accurate prognosis for
children who have genetic causes for their developmental
Stroustrup stressed, however, that the test isn't a screening
tool to predict the future mental ability of a child. "It would be
unethical to use it that way," she said.
"It's more of a diagnostic test for children who have pre-existing problems," Stroustrup said. Parents should wait until the child is a toddler and showing signs of developmental problems before considering this test, she added.
The test, called CytoScan Dx, analyzes a child's entire genome,
the FDA said in the statement. Affymetrix Inc., based in Santa
Clara, Calif., manufactures the test.
The FDA cautioned, however, that "the test results should only
be used in conjunction with other clinical and diagnostic
This recommendation is the most important part of Friday's
announcement, said Rahil Briggs, director of Pediatric Behavioral
Health Services at Montefiore Medical Center in New York City.
"I support all innovations that can reliably aid our ability to make accurate diagnoses, leading to appropriate interventions," Briggs said.
"However, any diagnosis of developmental delay requires multiple sources of information, including clinical observation by a trained professional," Briggs added.
Between 2 percent and 3 percent of U.S. children have some type
of intellectual disability. Many of these disabilities, such as
Down syndrome and DiGeorge syndrome, are associated with
chromosomal variations, according to the U.S. National Institutes
of Health and the American Academy of Pediatrics.
In approving the test, the FDA found that the screen could
"adequately" detect chromosome variations in areas of genetic code
linked with intellectual and developmental disabilities.
The agency also compared the new test with existing tests
commonly used for identifying a particular developmental delay or
intellectual disability. That comparison showed that the new test
was better at spotting certain chromosomal abnormalities.
Dr. David Mendez, a neonatologist at Miami Children's Hospital,
advised parents to be cautious about having such a test.
"Any genetic testing you do of your child has to be in consultation with a pediatric geneticist," he said.
Mendez said he'd also restrict the test to children who already
show signs of a developmental problem.
U.S. Centers for Disease Control and
Preventionfor more on child development.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.